Abstract
Due to the enormous potential of gene therapy, the optimization of DNA and RNA delivery for targeting cells is of great interest. The basis for this is optimized in vitro gene delivery, which was investigated in more detail in this dissertation. In order to improve the therapy of cardiovascular diseases, MCEC, HL-1 cells and MCF as heart-specific cells and Calu-3 as lung cells were investigated in greater depth. Furthermore, SK-N-SH cells were selected as interesting target cells for basic research into neurological disorders. In this dissertation, research was conducted on optimal cell type specific delivery vehicles for DNA delivery using adeno-associated viruses (AAV), specifically AAV2, AAV9 and AAV9-SIRSPPS, as well as Lipid-Polymer Hybrid Nanoparticles (LPNs) for mRNA delivery. As a comparative gold standard, the experiments were carried out using the Lipofectamines Lipofectamine 3000 and Lipofectamine LTX for DNA transfections, as well as Lipofectamine MessengerMAX for mRNA transfections. GFP was used as the gene of interest in each case. The efficiency of transfection or transduction in the cells was determined using flow cytometry, qPCR and fluorescence microscopy, while the WST-1 assay and the MTT assay were used to measure the toxicity of each vehicle. The viral transduction showed AAV9-SIRSPPS to be a particularly efficient vector, outperforming AAV2 and AAV9 in the transduction of MCEC, HL-1 cells, MCF and especially SK-N-SH cells. However, the Lipofectamines were confirmed as the most efficient vectors in DNA delivery in vitro in terms of the percentage of GFP positive cells, the intensity of the measured GFP signal and cell viability in HL-1 cells, MCF and Calu-3 cells. Due to the outstanding results of AAV9-SIRSPPS in the transduction of SK-N-SH cells with transduction rates of more than 80 % and well preserved cell viability, the transcriptome of the transduced cells was analyzed by next generation sequencing to identify possible off-targets. It turned out that although the transcriptome showed alterations in terms of increased immune response and other alterations, these were not very pronounced and AAV9-SIRSPPS proved to be an excellent vehicle. In the second part of the dissertation, different LPNs were compared to Lipofectamine MessengerMAX with regard to in vitro mRNA transfections. The LPNs used differed not only in terms of the amount of mRNA administered, but especially in their composition. The remarkable aspect here is that the LPNs are a hybrid consisting of a polymeric PLGA core and an outer lipid layer to which the mRNA is bound and thus belong to a new, relatively unexplored variant of nanocarriers. Two different LPNs were researched in detail in this dissertation, with the lipid shell of one being composed of 100 % DOTMA and the other of 70 % DOPE and 30 % DOTMA. It turned out that Lipofectamine MessengerMAX significantly outperformed LPNs in all cell lines except Calu-3 cells. It was particularly striking that although the LPNs were able to transfect a large number of cells with GFP, the intensity was quite low. Nevertheless, a positive finding with regard to the LPNs is that nanocarriers consisting of DOPE in particular tend to have potential for successful application and lead to the best transfection of Calu-3 cells of all the vehicles tested, including in DNA delivery. In summary, it can be said that Lipofectamines are still a very good vehicle in vitro. Except in Calu-3 cells, LPNs appear to be inferior to the other transfection methods established in vitro. However, a great finding was the AAV9-SIRSPPS as an excellent, in research quite unexplored vehicle, which appears to be efficient in almost all cell lines, especially in SK-N-SH cells. Furthermore, next generation sequencing revealed that viral transduction using AAV9-SIRSPPS is a relatively safe method with great potential for in vivo research and application.